ANALYSIS: Teva takes it step by step in Brazil
This article was originally published in Scrip
While Teva is known as a generics giant in most markets, in Brazil things are different. Here the firm is more active as an innovator, although not for want of trying to make its mark in the Brazilian generics space. The firm talked to Scrip about its step by step approach and why this challenging market is still worth the trouble.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.